Gilead Sciences stock: Scotiabank keeps USD 177.00 target, little changed pre-market
Published on 10/21/2026 at 08:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and agenda
- On October 20, 2026, Scotiabank analyst Louise Chen retained a Buy rating and a USD 177.00 price target.
- Gilead’s third-quarter 2026 financial results are scheduled for October 29, 2026.
- Gilead Sciences stock trades pre-market at EUR 139.24 at 8:56 a.m. CEST at Lang & Schwarz on October 21, 2026, minus 0.01 percent versus the Xetra close of October 20, 2026.
On October 20, 2026, Louise Chen of Scotiabank maintained a Buy rating on Gilead Sciences and a USD 177.00 price target, according to Markets Insider. Gilead Sciences stock trades pre-market at EUR 139.24 at 8:56 a.m. CEST at Lang & Schwarz on October 21, 2026, minus 0.01 percent versus the Xetra close of October 20, 2026 (EUR 139.26).
Scotiabank keeps its target
Scotiabank’s report kept its Buy rating and set the price target at USD 177.00. The report was published on October 20, 2026, and attributed the analyst action to Louise Chen.
Ahead of the Xetra open
The move is minus EUR 0.02, placing the stock slightly below the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead and the day
Gilead develops, manufactures and markets therapeutic products in virology, oncology and inflammation, according to its corporate website and MarketScreener. The next scheduled company date is October 29, 2026, when Gilead is listed as due to release its third-quarter financial results, according to MarketScreener.
Market context: Market report S&P 500.
